FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
PH12021552352B1Active Publication Date: 2026-07-31JANSSEN PHARMA NV
0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- PH · PH
- Patent Type
- Patents
- Current Assignee / Owner
- JANSSEN PHARMA NV
- Filing Date
- 2021-09-24
- Publication Date
- 2026-07-31
Abstract
Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor.
Need to check novelty before this filing date? Find Prior Art